Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Accumulated Expenses data on file, last reported at $69.8 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 811.51% year-over-year to $69.8 million in Q1 2026; TTM through Mar 2026 was $69.8 million, a 811.51% increase from a year earlier, with the FY2025 full-year figure at $97.8 million, up 7.44% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $69.8 million, down from $97.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for DNLI reached as high as $97.8 million in Q4 2025 and fell as low as $4.8 million in Q3 2024.
• Historically, Accumulated Expenses has averaged $29.3 million across 5 years, with a median of $10.3 million in 2023.
• Across the five-year window, Accumulated Expenses slumped 70.45% in 2024 and soared 811.51% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $66.7 million in 2022, then advanced by 2.71% to $68.5 million in 2023, then surged by 32.95% to $91.1 million in 2024, then increased by 7.44% to $97.8 million in 2025, then fell by 28.69% to $69.8 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $69.8 million in Q1 2026, $97.8 million in Q4 2025, and $4.9 million in Q3 2025.